skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: THE EFFECT OF ORALLY ADMINISTERED EPSILON AMINOCAPROIC ACID ON THE DEPOSITION AND/OR RETENTION OF RADIOIODINATED FIBRINOGEN AND ANTIBODIES TO FIBRINOGEN IN SUBCUTANEOUS RAT PLASMA CLOTS AND TURPENTINE-INDUCED ABSCESSES OF THE RAT

Technical Report ·
OSTI ID:4739172

Treatment of metastatic cancer through the use of highly radioactive labeled tumor-localizing antibodies would have the advantage over conventional radiation therapy techniques of delivering large doses of radiation to areas of malignancy while at the same time sparing vital normal tissue from excessive radiation. Intravenously administered I/sup 131/-labeled rat fibrinogen and antibodies to rat fibrin or fibrinogen were found to localize with considerable specificity in the rat-carried Murphy-Sturm lymphosarcoma. lt was suggested that fibrin deposition in tumors is a phenomenon associated with the growth of these tumors and may be of significance in rapidly growing tumors. An apparent lack of I/sup 131/-fibrinogen localization was observed in some transplantable rat tumors, such as the Walker carcinoma 256. The hypothesis that fibrin deposition is masked by its subsequent rapid removal by fibrinolytic processes was investigated. Data are presented from an investigation of the in vivo antifibrinolytic properties of epsilon aminocapronic acid (EACA), a potent in vitro fibrinolytic inhibitor. Two basic test systems, both using the rat as an experimental animal, were employed. The first involved measuring the effect of orally administered EACA on the retention of subcutaneous clots labeled with either I/sup 131/-fibrinogen or I/sup 131/-antibody against rat fibrinogen. The second system involved measuring the effect of EACA treatment on the deposition and retention of intravenously injected I/sup 131/-fibrinogen and I/sup 131/- antibody in subcutaneous turpentine-induced abscesses. Data indicate that EACA is a potent in vivo anti-fibrinolytic agent and that the mechanism by which EACA treatment brings about increased tumor localization of I/sup 131/-fibrinogen and I/sup 131/antibody is the inhibition of their subsequent removal by fibrinolytic processes. (C.H.)

Research Organization:
Rochester, UN.Y. Univ. ATomic Energy Project
DOE Contract Number:
W-7401-ENG-49
NSA Number:
NSA-17-017766
OSTI ID:
4739172
Report Number(s):
UR-623
Resource Relation:
Other Information: Orig. Receipt Date: 31-DEC-63
Country of Publication:
United States
Language:
English